Oncorus, a Massachusetts-based biotech startup, shuts down after laying off most of its staff. The company’s board unanimously approved the closure, ending its efforts in cancer therapy development. The move follows a pattern of biotech startups discontinuing programs amid funding challenges.
Oncorus’s board liquidates the RNA-focused biotech following mass layoffs that left the company with nearly no staff. The decision comes after the company’s workforce was drastically reduced, rendering it effectively non-operational. Oncorus had previously focused on RNA-based therapies but will now cease operations entirely.
Oncorus, an RNA-focused biotech company, has laid off substantially all of its employees amid financial distress. The move signals severe operational challenges as the company faces potential bankruptcy. Oncorus has not disclosed further details about its future operations or restructuring plans.
Oncorus, Inc. implements a workforce reduction plan to streamline operations. The company cites strategic realignment as the primary driver behind the decision, though no specific details on job cuts or affected roles are disclosed. This move follows broader industry trends in cost optimization amid economic uncertainty.
Oncorus reduces its workforce by 20% amid a pause in drug development, continuing work on only one treatment. The Boston-based biotech company scales back operations as it focuses resources on a single project.
Oncorus abandons its herpes simplex virus (HSV)-based drug program for solid tumors, which was previously tested in combination with Merck’s Keytruda. The decision follows a shift in strategy and triggers workforce reductions, affecting 15% of employees. The move raises uncertainty over the status of other experimental candidates in the pipeline.